Alistair Reid Venom Research Unit

Liverpool, United Kingdom

Alistair Reid Venom Research Unit

Liverpool, United Kingdom

Time filter

Source Type

News Article | April 20, 2016
Site: www.nature.com

When the medical charity Médecins Sans Frontières called the worldwide shortage of snake antivenom a public-health crisis last September, Brazilian biochemist Paulo Lee Ho wasn’t surprised. He has spent his career at São Paulo’s Butantan Institute searching for better ways to create antivenom to treat bites from coral snakes. Conventional methods rely on natural coral-snake venom, which is hard to come by: the snakes produce only small amounts with each bite and are hard to raise in captivity. So Ho and others have turned to proteomics and synthetic biology in the hope of improving the quality and availability of antivenom. “We need a new way to meet the demand for antivenom from the Ministry of Health,” he says. These efforts are now bearing fruit. Last month, Ho and his colleagues reported1 that they had engineered short pieces of DNA that, when injected into mice, triggered antibodies against coral-snake venom. The scientists then boosted the animals’ immune response by injecting them with small pieces of synthetic venom antibodies synthesized in Escherichia coli bacteria. In a separate study also published last month2, another group of researchers in Brazil used synthetic antibody fragments to neutralize the effects of bites by the pit viper Bothrops jararacussu. Such progress is encouraging, given the severe medical burden caused by snakebites in the developing world, says Robert Harrison, head of the Alistair Reid Venom Research Unit at the Liverpool School of Tropical Medicine, UK. Each year, around 90,000 people die after being bitten by venomous snakes3. Yet antivenoms are still made using a method that has not changed for more than a century. Large animals, typically horses, are injected with small amounts of purified proteins extracted from snake venom, which prompts the production of antibodies. Plasma containing these antibodies is then given to snakebite victims. But this life-saving treatment is limited in important ways. Each antivenom is effective against only a single species or, at most, a small group. And the drugs must be refrigerated, a major problem in tropical countries without reliable electricity. “When you think about it, it’s amazing these antivenoms work at all,” says Leslie Boyer, director of the Venom, Immunochemistry, Pharmacology and Emergency Response Institute at the University of Arizona in Tucson. The number of pharmaceutical companies that make antivenoms is declining, because the drugs are not very profitable. In 2010, for instance, pharmaceutical giant Sanofi of Paris, ended production of the antivenom Fav-Afrique, which is designed to treat the bites of ten of Africa’s most poisonous snakes. Ho hopes that his approach will help to fill this void. Rather than relying on venom milked from live coral snakes, he began with small pieces of coral-snake DNA that code for venom toxins. He and his colleagues injected these DNA pieces into mice to prime their immune systems; a month later, they gave the animals a booster shot containing synthetic venom antibodies. Only 60% of mice injected with a lethal dose of coral-snake venom survived after receiving Ho’s experimental treatment, compared to nearly 100% for existing antivenoms. But Ho is undaunted. “This result shows there are other ways to obtain neutralizing antibodies,” he says. “Maybe to get better results, we need to try again but use more antibodies. We just don’t know yet.” The second Brazilian team, led by molecular biologist Carla Fernandes of the Fundação Oswaldo Cruz (Fiocruz) biomedical research institute in Porto Velho, tested a different technique, using a phage display library to make synthetic versions of the antibodies that llamas produced when they were injected with B. jararacussu snake venom. Giving these antibodies to snakebite victims would eliminate the need to use animal plasma. It also could reduce muscle damage and tissue death at the site of the bite, compared to traditional antivenoms, because the synthetic antibodies are smaller and better able to penetrate into tissue. The path to newer antivenoms isn't straight, but researchers believe that moving quickly is key. “There has been significant, rapid progress in this area, but it needs to be fast. There are too many people dying from what is essentially a preventable disease,” says Harrison. To Boyer, however, the antivenom shortage is not caused by a lack of science. “It costs 14 bucks to make a vial of antivenom that costs US$14,000 in the US,” she says. “You’re not going to get cheaper than that. The expensive parts aren’t the science — it’s everyone wanting a cut of the profits that drives the price up and puts it out of reach.”


Reyes-Velasco J.,University of Texas at Arlington | Card D.C.,University of Texas at Arlington | Andrew A.L.,University of Texas at Arlington | Shaney K.J.,University of Texas at Arlington | And 5 more authors.
Molecular Biology and Evolution | Year: 2015

Snake venom gene evolution has been studied intensively over the past several decades, yet most previous studies have lacked the context of complete snake genomes and the full context of gene expression across diverse snake tissues. We took a novel approach to studying snake venom evolution by leveraging the complete genome of the Burmese python, including information from tissue-specific patterns of gene expression. We identified the orthologs of snake venom genes in the python genome, and conducted detailed analysis of gene expression of these venom homologs to identify patterns that differ between snake venom gene families and all other genes. We found that venom gene homologs in the python are expressed in many different tissues outside of oral glands, which illustrates the pitfalls of using transcriptomic data alone to define "venom toxins." We hypothesize that the python may represent an ancestral state prior to major venom development, which is supported by our finding that the expansion of venom gene families is largely restricted to highly venomous caenophidian snakes. Therefore, the python provides insight into biases in which genes were recruited for snake venom systems. Python venom homologs are generally expressed at lower levels, have higher variance among tissues, and are expressed in fewer organs compared with all other python genes. We propose a model for the evolution of snake venoms in which venom genes are recruited preferentially from genes with particular expression profile characteristics, which facilitate a nearly neutral transition toward specialized venom system expression. © 2014 The Author.


News Article | August 31, 2016
Site: www.nature.com

Abdulsalam Nasidi's phone rang shortly after midnight: Nigeria's health minister was on the line. Nasidi, who worked at the country's Federal Ministry of Health, learnt that he was needed urgently in the Benue valley to investigate a cluster of dying patients. People were bleeding out of their noses, their mouths, their eyes. Names of spine-chilling viruses such as Ebola, Lassa and Marburg raced through Nasidi's mind. When he arrived in Benue, he found people splayed on the ground and tents serving as makeshift hospital wards and morgues. But Nasidi quickly realized that the cause of the mystery illness was millions of times larger than any virus. The onset of the rainy season had brought the start of spring planting for farmers in the valley, and flooding had disturbed the resident carpet vipers (Echis ocellatus). Many farmers were simply too poor to buy boots — and their exposed feet became targets for the highly venomous snakes. Nasidi wanted to help, but he found himself with limited tools. He had only a small amount of antivenom with which to neutralize the toxin — and it quickly ran out. Once the hospital exhausted its supply, people stopped coming. No one knows how many people were killed. In an average year, hundreds of Nigerians die from snakebite, and that rainy season, which started in 2012, was far from average. Snakebites are a growing public-health crisis. According to the World Health Organization, around 5 million people worldwide are bitten by snakes each year; more than 100,000 of them die and as many as 400,000 endure amputations and permanent disfigurement. Some estimates point to a higher toll: one systematic survey concluded that in India alone, more than 45,000 people died in 2005 from snakebite1 — around one-quarter the number that died from HIV/AIDS (see 'The toll of snakebite'). “It's the most neglected of the world's neglected tropical diseases,” says David Williams, a toxinologist and herpetologist at the University of Melbourne, Australia, and chief executive of the non-profit organization Global Snakebite Initiative in Herston. Many of those bites are treatable with existing antivenoms, but there are not enough to go around. This long-standing problem became international news in September 2015, when Médecins Sans Frontières (MSF, also known as Doctors Without Borders) announced that the last remaining vials of the antivenom Fav-Afrique, used to treat bites from several of Africa's deadliest snakes, were about to expire. The French pharma giant Sanofi Pasteur in Lyons had decided to cease production in 2014. MSF estimates that this could cause an extra 10,000 deaths in Africa each year — an “Ebola-scale disaster”, according to Julien Potet, a policy adviser for MSF in Paris. Yet, because most of those affected by snakebites are in the poorest regions of the world, the issue has been largely ignored. In May, however, the crisis was discussed for the first time at the annual World Heath Assembly meeting in Geneva, Switzerland. The world's handful of snakebite specialists gathered in a small conference room in the Palais des Nations — although they shared concern over the problem, they were split about how to solve it. Many want to use synthetic biology and other high-tech tools to develop a new generation of broad-spectrum antivenoms. Others argue that existing antivenoms are safe, effective and low cost, and that the focus should be on improving their production, price and use. “From the physician perspective, patient care and public health comes before anything new,” says Leslie Boyer, who directs an institute dedicated to antivenom study at the University of Arizona, Tucson. The debate mirrors those around many other developing-world challenges, from improving agriculture to providing clean drinking water. Do people need high-tech solutions, or can cheaper, lower-tech remedies do the job? The answer is simple to Jean-Philippe Chippaux, a physician working on snakebite for the French Institute of Research for Development in Cotonou, Benin. “We have the ability to fix this problem now. We just lack the will to do it,” he says. Every December, Williams sees snakebite victims flood into the Port Moresby General Hospital in Papua New Guinea. Nearly all of them were bitten by the taipan (Oxyuranus scutellatus), one of the world's deadliest snakes, which emerges at the start of the rainy season. The venom stops a victim's blood from clotting, paralyses muscles and leads to a slow, agonizing death. It seems a far cry from Australia, where Williams is based. “There's this incredible suffering just 90 minutes away from the modern world,” he says. Yet Williams knows that these people are the lucky ones. The hospital ward, which might be treating as many as eight taipan victims at any time, is often the only place in the country with antivenom drugs. Without them, some 10–15% of all snakebite victims die; with them, just 0.5% do. The situation is reflected around the world. “Many countries don't want to admit that they have such a primeval-sounding problem,” Chippaux says. The method used to make antivenom has changed little since French physician Albert Calmette developed it in the 1890s. Researchers inject minuscule amounts of venom, milked from snakes, into animals such as horses or sheep to stimulate the production of antibodies that bind to the toxins and neutralize them. They gradually increase doses of venom until the animal is pumping out huge amounts of neutralizing antibodies, which are purified from the blood and administered to snakebite victims. Across much of Latin America, government-funded labs typically produce antivenoms and distribute them free of charge. But in other areas, especially sub-Saharan Africa, these life-saving medications are too often out of reach. Many governments lack the infrastructure or political will to purchase and distribute antivenom. Bribery and corruption often jack up the price of an otherwise inexpensive drug from a typical wholesale cost of US$18 to $200 per vial to a retail cost between $40 and $24,000 for a complete treatment, according to a 2012 analysis2. Not all hospitals and clinics can afford the antivenom, and some won't risk buying it because their patients either can't pay for it or won't, because they doubt that it really works. With no reliable market for the medicines, some pharmaceutical companies have halted production. Sanofi Pasteur stopped making Fav-Afrique because, at an average retail price of around $120 per vial, it just couldn't sell enough to make production worthwhile. A total of 35 government or commercial manufacturers produce antivenom for distribution around the world, but only 5 now make the drugs for sub-Saharan Africa. In the absence of medicines, snakebite victims have been known to drink petrol, electrocute themselves or apply a poultice of cow dung and water to the bite, says Tim Reed, executive director of Health Action International in Amsterdam. But there are also problems with the drugs themselves, says Robert Harrison, head of the Alistair Reid Venom Research Unit at the Liverpool School of Tropical Medicine, UK. They often have a limited shelf life and require continuous refrigeration, which is a problem in remote areas without electricity. And many are effective against just one species of snake, so clinics need an array of medicines constantly on hand. (A few, such as Fav-Afrique, combine antibodies to create a broad-spectrum product.) Venoms from spiders and scorpions typically have only one or two toxic proteins; snake venoms can have more than ten times that amount. They are a “pandemonium of molecules”, says Alejandro Alagón, a toxinologist at the National Autonomous University of Mexico in Mexico City. Researchers do not always know which proteins in this toxic soup are the damaging ones — which is why some think that smarter biology could help. Ten years ago, teams led by Harrison and José María Gutiérrez, a toxinologist at the University of Costa Rica in San José, began parallel efforts to create a universal antivenom for sub-Saharan Africa using 'venomics' and 'antivenomics'. The aim is to identify destructive proteins in venoms using an array of techniques, ranging from genome sequencing to mass spectrometry, and then find the specific parts, known as epitopes, that provoke an immunological response and are neutralized by the antibodies in antivenom drugs. The ultimate goal is to use the epitopes to produce antibodies synthetically, using cells rather than animals, and develop antivenoms that are effective against a wide range of snake species in one part of the world. The scientists have made slow but steady progress. Last year, Gutiérrez and his colleagues separated and identified the most toxic proteins from a family of venomous snakes known as elapids (Elapidae). By combining information about the abundance of each protein and how lethal it is to mice, the team created a toxicity score to indicate how important it was to neutralize a protein with antivenom, a first step towards making the treatment3. In March this year, a Brazilian team reported that they had gone further, designing short pieces of DNA that encode key toxic epitopes in the venom of the coral snake (Micrurus corallinus), a member of the elapid family4. Mice were injected with the DNA using a technique that enabled some to generate antibodies against coral-snake venom, and the group enhanced the mice's immune responses by injecting them with synthetic antibodies manufactured in bacterial cells. These and other advances led Harrison to estimate that the first trials of new antivenoms in humans could be just three or four years away. But with so few researchers working on the problem, a paucity of funding and the biological complexity of snake venoms, he and others admit that this is an optimistic prediction. Despite the growing literature on antivenomics, Alagón and Chippaux aren't convinced that the approach will help. Alagón estimates that newly developed antivenoms would need to be priced at tens of thousands of dollars per dose to be financially viable to produce, and that no biotech or pharma company would manufacture one without substantial government subsidies. Compare that, he says, to the rock-bottom price of many existing antivenoms. “You can't get cheaper than that,” he says. “We can make an entire lot of antivenoms in one day using technology that's been available for 80 years.” Finding someone to produce new medications might be a greater challenge than actually developing them, Williams acknowledges: governments or non-governmental organizations (NGOs) will almost certainly have to step in to help to defray the development costs. But he argues that now is the time to research alternative approaches. These could “revolutionize the treatment of snakebite envenoming in the next 10–15 years”, Williams says. All these tensions, brewing for nearly a decade, came to a head at the Geneva meeting in May. Around 75 scientists, public-health experts and health-assembly delegates crowded around three long tables in a third-floor conference room at the United Nations Headquarters. Spring rain pelted the tall windows. Lights were dimmed, and then the screams of a toddler filled the room. A short documentary co-produced by the Global Snakebite Initiative told the story of a girl bitten by a cobra whose parents carried her for days over rocky roads in Africa to find antivenom. They arrived in time — the girl survived — but she lost the use of her arm. Her sister had already died after a bite from the same snake. Convincing attendees of the scale of the problem was the meeting's primary goal; how to solve it came next. For 90 minutes, scientists and NGOs made short, impassioned speeches laying out the scope of the issue and the variety of problems that they faced. At the centre of each presentation was the same message: we need more antivenom. But the meeting was strained. Chippaux and representatives of the African Society of Venomology were disappointed and angry that so few Africans had been invited to speak, even though the continent is where antivenom shortages are most acute. “Our voice, our issues, were completely overlooked,” Chippaux says. Seated at the front of the room, group members whispered and gestured frantically to each other, and Chippaux barely managed to keep them from storming out. They argue that the current antivenom shortage stems from Africa's reliance on foreign companies and governments for its drugs, and that the only solution lies in building up infrastructure in Africa to produce its own high-quality antivenom. Alagón views antivenomics as a dangerous diversion. “It's distracting many brilliant minds and resources from improving antivenoms using existing technology,” he says. “Perhaps by 2050 this will be the standard technique, but the problem is now.” Williams and Gutiérrez take a middle ground. They feel that the problem requires attacks on all fronts. As well as innovation, Gutiérrez calls for existing manufacturers to step up the production of current drugs. There are signs of this happening already. Latin America has a long history of producing antivenoms both for its own needs and for those of countries around the world, and even before Sanofi Pasteur announced that it would cease production of Fav-Afrique, Costa Rica, Brazil and Mexico were testing antivenoms for different parts of Africa. One product, EchiTAb-Plus-ICB, is produced by Costa Rica and effective against a range of African viper species; it completed clinical trials in 2014 and is now available for use. Several other antivenoms are expected to be ready in the next two years. The drugs should be affordable: government labs in Costa Rica have already indicated that they will not seek to make money from the antivenoms, just recoup their expenditures. But beyond that, the way forward remains murky. Williams knows that the World Heath Assembly meeting was just a start. Inevitably, more meetings will be needed to produce a concrete action plan. But the discussion still gave him and some others a renewed sense of hope that the international community is beginning to take snakebite seriously — momentum they hope to build on by banging away at the topic at conferences and in the media. Boyer says that whatever solution the snakebite field decides on, the most important thing is to “break the cycle of antivenom failure in Africa”. Doing that requires building trust from governments, health-care workers and the public that the drugs are safe and effective, that clinics will have antivenom on hand, and that people will be able to afford treatment. “Without that, you've got nothing,” Boyer says. Educating local clinics on how to care for snakebite victims and administer treatments in a timely manner would also go a long way towards preventing deaths. Speaking of the devastation he saw in Benue, Nasidi says that something as simple as providing boots for poor farmers would have helped to prevent much of the suffering and death that he witnessed. It's perhaps the ultimate in low-tech methods in snakebite protection: shielding vulnerable human skin.”


Vaiyapuri S.,University of Reading | Wagstaff S.C.,Alistair Reid Venom Research Unit | Harrison R.A.,Alistair Reid Venom Research Unit | Gibbins J.M.,University of Reading | And 2 more authors.
PLoS ONE | Year: 2011

Background: Serine proteases are major components of viper venom and target various stages of the blood coagulation system in victims and prey. A better understanding of the diversity of serine proteases and other enzymes present in snake venom will help to understand how the complexity of snake venom has evolved and will aid the development of novel therapeutics for treating snake bites. Methodology and Principal Findings: Four serine protease-encoding genes from the venom gland transcriptome of Bitis gabonica rhinoceros were amplified and sequenced. Mass spectrometry suggests the four enzymes corresponding to these genes are present in the venom of B. g. rhinoceros. Two of the enzymes, rhinocerases 2 and 3 have substitutions to two of the serine protease catalytic triad residues and are thus unlikely to be catalytically active, though they may have evolved other toxic functions. The other two enzymes, rhinocerases 4 and 5, have classical serine protease catalytic triad residues and thus are likely to be catalytically active, however they have glycine rather than the more typical aspartic acid at the base of the primary specificity pocket (position 189). Based on a detailed analysis of these sequences we suggest that alternative splicing together with individual amino acid mutations may have been involved in their evolution. Changes within amino acid segments which were previously proposed to undergo accelerated change in venom serine proteases have also been observed. Conclusions and Significance: Our study provides further insight into the diversity of serine protease isoforms present within snake venom and discusses their possible functions and how they may have evolved. These multiple serine protease isoforms with different substrate specificities may enhance the envenomation effects and help the snake to adapt to new habitats and diets. Our findings have potential for helping the future development of improved therapeutics for snake bites. © 2011 Vaiyapuri et al.


Currier R.B.,Alistair Reid Venom Research Unit | Harrison R.A.,Alistair Reid Venom Research Unit | Rowley P.D.,Alistair Reid Venom Research Unit | Laing G.D.,Molecular and Biochemical Parasitology Group | Wagstaff S.C.,Alistair Reid Venom Research Unit
Toxicon | Year: 2010

Bitis arietans is considered one of the most medically significant snakes in Africa, primarily due to a combination of its extensive geographical distribution, common occurrence and highly potent haemorrhagic and cytotoxic venom. Our investigation has revealed a remarkable degree of intra-species variation between pooled venom samples from different geographical origins across sub-Saharan Africa and Arabia, and within a group of individual specimens from the same origin in Nigeria as determined by a combination of immunological, biochemical and proteomic assays. We demonstrate significant quantitative and qualitative differences between B. arietans venom in terms of protein expression, immunogenicity and activity of snake venom metalloproteinases (SVMPs); toxins with a primary role in the haemorrhagic and tissue-necrotic pathologies suffered by envenomed victims. Specifically, we have identified a processed PII SVMP that exhibits striking inter-specimen variability. © 2009 Elsevier Ltd.


Casewell N.R.,Alistair Reid Venom Research Unit | Casewell N.R.,Bangor University | Wagstaff S.C.,Alistair Reid Venom Research Unit | Harrison R.A.,Alistair Reid Venom Research Unit | And 2 more authors.
Molecular Biology and Evolution | Year: 2011

Gene duplication is a key mechanism for the adaptive evolution and neofunctionalization of gene families. Large multigene families often exhibit complex evolutionary histories as a result of frequent gene duplication acting in concordance with positive selection pressures. Alterations in the domain structure of genes, causing changes in the molecular scaffold of proteins, can also result in a complex evolutionary history and has been observed in functionally diverse multigene toxin families. Here, we investigate the role alterations in domain structure have on the tempo of evolution and neofunctionalization of multigene families using the snake venom metalloproteinases (SVMPs) as a model system. Our results reveal that the evolutionary history of viperid (Serpentes: Viperidae) SVMPs is repeatedly punctuated by domain loss, with the single loss of the cysteine-rich domain, facilitating the formation of P-II class SVMPs, occurring prior to the convergent loss of the disintegrin domain to form multiple P-I SVMP structures. Notably, the majority of phylogenetic branches where domain loss was inferred to have occurred exhibited highly significant evidence of positive selection in surface-exposed amino acid residues, resulting in the neofunctionalization of P-II and P-I SVMP classes. These results provide a valuable insight into the mechanisms by which complex gene families evolve and detail how the loss of domain structures can catalyze the accelerated evolution of novel gene paralogues. The ensuing generation of differing molecular scaffolds encoded by the same multigene family facilitates gene neofunctionalization while presenting an evolutionary advantage through the retention of multiple genes capable of encoding functionally distinct proteins. © 2011 The Author.


Casewell N.R.,Bangor University | Wagstaff S.C.,Alistair Reid Venom Research Unit | Harrison R.A.,Alistair Reid Venom Research Unit | Wuster W.,Bangor University
Molecular Biology and Evolution | Year: 2011

The proliferation of gene data from multiple loci of large multigene families has been greatly facilitated by considerable recent advances in sequence generation. The evolution of such gene families, which often undergo complex histories and different rates of change, combined with increases in sequence data, pose complex problems for traditional phylogenetic analyses, and in particular, those that aim to successfully recover species relationships from gene trees. Here, we implement gene tree parsimony analyses on multicopy gene family data sets of snake venom proteins for two separate groups of taxa, incorporating Bayesian posterior distributions as a rigorous strategy to account for the uncertainty present in gene trees. Gene tree parsimony largely failed to infer species trees congruent with each other or with species phylogenies derived from mitochondrial and single-copy nuclear sequences. Analysis of four toxin gene families from a large expressed sequence tag data set from the viper genus Echis failed to produce a consistent topology, and reanalysis of a previously published gene tree parsimony data set, from the family Elapidae, suggested that species tree topologies were predominantly unsupported. We suggest that gene tree parsimony failure in the family Elapidae is likely the result of unequal and/or incomplete sampling of paralogous genes and demonstrate that multiple parallel gene losses are likely responsible for the significant species tree conflict observed in the genus Echis. These results highlight the potential for gene tree parsimony analyses to be undermined by rapidly evolving multilocus gene families under strong natural selection. © The Author 2010. Published by Oxford University Press on behalf of the Society for Molecular Biology and Evolution. All rights reserved.


Casewell N.R.,Alistair Reid Venom Research Unit | Casewell N.R.,Bangor University | Huttley G.A.,Australian National University | Wuster W.,Bangor University
Nature Communications | Year: 2012

Phylogenetic analyses of toxin gene families have revolutionised our understanding of the origin and evolution of reptile venoms, leading to the current hypothesis that venom evolved once in squamate reptiles. However, because of a lack of homologous squamate non-toxin sequences, these conclusions rely on the implicit assumption that recruitments of protein families into venom are both rare and irreversible. Here we use sequences of homologous non-toxin proteins from two snake species to test these assumptions. Phylogenetic and ancestral-state analyses revealed frequent nesting of 'physiological' proteins within venom toxin clades, suggesting early ancestral recruitment into venom followed by reverse recruitment of toxins back to physiological roles. These results provide evidence that protein recruitment into venoms from physiological functions is not a one-way process, but dynamic, with reversal of function and/or co-expression of toxins in different tissues. This requires a major reassessment of our previous understanding of how animal venoms evolve. ©2012 Macmillan Publishers Limited. All rights reserved.


Casewell N.R.,Bangor University | Casewell N.R.,Alistair Reid Venom Research Unit | Wuster W.,Bangor University | Vonk F.J.,Naturalis Biodiversity Center | And 2 more authors.
Trends in Ecology and Evolution | Year: 2013

Venoms have evolved on numerous occasions throughout the animal kingdom. These 'biochemical weapon systems' typically function to facilitate, or protect the producing animal from, predation. Most venomous animals remain unstudied despite venoms providing model systems for investigating predator-prey interactions, molecular evolution, functional convergence, and novel targets for pharmaceutical discovery. Through advances in 'omic' technologies, venom composition data have recently become available for several venomous lineages, revealing considerable complexity in the processes responsible for generating the genetic and functional diversity observed in many venoms. Here, we review these recent advances and highlight the ecological and evolutionary novelty of venom systems. © 2012 Elsevier Ltd.


Currier R.B.,Alistair Reid Venom Research Unit | Calvete J.J.,Institute Biomedicina Of Valencia | Sanz L.,Institute Biomedicina Of Valencia | Harrison R.A.,Alistair Reid Venom Research Unit | And 2 more authors.
PLoS ONE | Year: 2012

Venom is a critical evolutionary innovation enabling venomous snakes to become successful limbless predators; it is therefore vital that venomous snakes possess a highly efficient venom production and delivery system to maintain their predatory arsenal. Here, we exploit the unusual stability of messenger RNA in venom to conduct, for the first time, quantitative PCR to characterise the dynamics of gene expression of newly synthesised venom proteins following venom depletion. Quantitative PCR directly from venom enables real-time dynamic studies of gene expression in the same animals because it circumvents the conventional requirement to sacrifice snakes to extract mRNA from dissected venom glands. Using qPCR and proteomic analysis, we show that gene expression and protein re-synthesis triggered by venom expulsion peaks between days 3-7 of the cycle of venom replenishment, with different protein families expressed in parallel. We demonstrate that venom re-synthesis occurs very rapidly following depletion of venom stores, presumably to ensure venomous snakes retain their ability to efficiently predate and remain defended from predators. The stability of mRNA in venom is biologically fascinating, and could significantly empower venom research by expanding opportunities to produce transcriptomes from historical venom stocks and rare or endangered venomous species, for new therapeutic, diagnostic and evolutionary studies. © 2012 Currier et al.

Loading Alistair Reid Venom Research Unit collaborators
Loading Alistair Reid Venom Research Unit collaborators